Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecan (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer[1].
Purity:
98.61
CAS Number:
[2924909-11-3]
Target:
Antibody-Drug Conjugates (ADCs),EGFR
Application Notes:
MCE Product type: ADC Related
* VAT and and shipping costs not included. Errors and price changes excepted